Blood Proteins Patents (Class 435/69.6)
-
Patent number: 11834494Abstract: The present disclosure relates to antibodies specific to Zika virus and methods for detecting Zika virus infection in a subject. The present disclosure also relates to therapeutic antibodies useful in reducing viral load.Type: GrantFiled: July 26, 2017Date of Patent: December 5, 2023Assignee: Washington UniversityInventors: Michael S. Diamond, Daved Fremont, Haiyan Zhao, Estefania Fernandez, Derek Platt, Christopher Nelson
-
Patent number: 11834503Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, e.g., cancer.Type: GrantFiled: June 7, 2022Date of Patent: December 5, 2023Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.Inventors: Michael Monrad Grandal, Vikram Kjøller Bhatia, Torben Gjetting, Camilla Fröhlich, Gunther Roland Galler, Michael Kragh, Ivan David Horak, Thomas Bouquin, Mikkel Wandahl Pedersen
-
Patent number: 11834693Abstract: The present invention relates to a method for producing a fusion polynucleotide encoding a polypeptide of interest. The method comprises the steps of providing a first polynucleotide and a second polynucleotide, and contacting said first polynucleotide and second polynucleotide with a type IIs restriction endonuclease and a ligase under conditions that allow for the cleavage of the first polynucleotide and second polynucleotide by said type IIs restriction endonuclease and the ligation of the resulting cleavage products, thereby producing the fusion polynucleotide encoding the polypeptide of interest. The first polynucleotide comprises the 5? portion of an intron, and the second polynucleotide comprises the 3? portion of an intron. Further envisaged by the present invention is a polynucleotide encoding a polypeptide of interest, which, when transcribed in a eukaryotic host cell, is transcribed into a transcript comprising at least five introns which are heterologous to said polynucleotide.Type: GrantFiled: September 19, 2019Date of Patent: December 5, 2023Assignee: SANOFIInventors: Wulf Leuschner, Werner Dittrich, I, Joerg Birkenfeld, Marion Schneider
-
Patent number: 11834654Abstract: Isolated antigen binding molecules that specifically binds to a molecule comprising an amino acid sequence selected from the group consisting of GGGS (SEQ ID NO: 1), GGGGS (SEQ ID NO: 46) and related sequences are provided. The antigen binding molecules may be used in the methods provided herein.Type: GrantFiled: November 10, 2020Date of Patent: December 5, 2023Assignee: Kite Pharma, Inc.Inventors: Jed J. W. Wiltzius, Stuart A. Sievers
-
Patent number: 11827692Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell o growth to achieve high product titer cell cultures.Type: GrantFiled: March 8, 2023Date of Patent: November 28, 2023Assignee: AMGEN INC.Inventors: Brian D. Follstad, Rebecca E. McCoy, Arvia E. Morris
-
Patent number: 11820832Abstract: Provided herein are compositions, methods, and uses involving bispecific binding molecules that specifically bind to HER2, a receptor tyrosine kinase, and to CD3, a T cell receptor, and mediate T cell cytotoxicity for managing and treating disorders, such as cancer. Also provided herein are uses and methods for managing and treating HER2-related cancers.Type: GrantFiled: January 27, 2017Date of Patent: November 21, 2023Assignee: Memorial Sloan Kettering Cancer CenterInventors: Nai-Kong V. Cheung, Andres Lopez-Albaitero, Hong Xu
-
Patent number: 11820801Abstract: The present invention relates to a fusion protein comprising an extracellular domain of leucine-rich and immunoglobulin-like domains-1 (Lrig-1) protein and an immunoglobulin Fc region. The fusion protein provided in the present invention can interact with a ligand for Lrig-1 protein, which is present on effector T cells, to inhibit the interaction between the effector T cells and regulatory T cells (Treg cells) having the Lrig-1 protein on their surface, so that activity of the regulatory T cells is inhibited and activity of the effector T cells is maintained or elevated, thereby effectively inhibiting growth of cancer cells, in particular, solid cancer cells.Type: GrantFiled: April 26, 2019Date of Patent: November 21, 2023Assignee: Good T Cells, Inc.Inventors: Jung Ho Kim, Beom Seok Kim
-
Patent number: 11814441Abstract: The present invention provides antigen-binding polypeptides, including bi-specific antigen-binding polypeptides, that specifically bind to a first and a second target antigen with high affinity. The present invention also provides novel antigen-binding polypeptides that specifically bind to HER2 and antagonize HER2 activation. The invention also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen binding polypeptides. Methods of using antigen-binding polypeptide of the invention to treat disease, including cancer, are also encompassed by the invention.Type: GrantFiled: January 22, 2019Date of Patent: November 14, 2023Assignee: X-BODY, INC.Inventors: Yan Chen, Richard W. Wagner, Keming Zhang, Pascale Richalet
-
Patent number: 11807686Abstract: The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-L1 positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.Type: GrantFiled: May 30, 2018Date of Patent: November 7, 2023Assignee: Bristol-Myers Squibb CompanyInventors: James Novotny, Jr., Nils Lonberg, Cyrus Hedvat, Raphael Clynes, Darren Locke, John P. Cogswell, Jeffrey Jackson, Christopher Harbison, Robin Edwards
-
Patent number: 11789029Abstract: A unique pipeline is employed for biomarker discovery that entailed domain antibody phage display, next generation sequencing analysis, and nanotechnology strategies to generate antibody mimetics are disclosed. Also disclosed are the temporal biomarkers of traumatic brain injury and their methods of use. In some embodiments, the temporal biomarkers are synthetic peptides comprising the HCDR3 sequences identified using the disclosed pipeline. In some aspects, the synthetic peptides have less than 30 amino acid residues and comprise a biotin scaffold that is linked to the HCDR3 sequences.Type: GrantFiled: June 19, 2020Date of Patent: October 17, 2023Assignee: Arizona Board of Regents on Behalf of Arizona State UniversityInventors: Briana Martinez, Sarah Stabenfeldt, Chris Diehnelt, Nicholas Stephanopoulos, Crystal Willingham, Amanda Witten, Kendall Lundgreen
-
Patent number: 11780907Abstract: The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to the influenza hemagglutinin (HA) protein, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing influenza virus activity, thus providing a means of treating or preventing influenza infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the influenza HA for preventing viral attachment and/or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.Type: GrantFiled: January 24, 2019Date of Patent: October 10, 2023Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Lisa A. Purcell, Jonathan Viau, William Olson
-
Patent number: 11780915Abstract: The present disclosure is directed to human protease activated receptor 4 (PAR4) binding proteins (e.g. antibodies). In particular, anti-PAR4 binding proteins which are antagonists of human PAR4, as well as methods and uses thereof.Type: GrantFiled: September 11, 2018Date of Patent: October 10, 2023Assignee: MONASH UNIVERSITYInventors: Justin Hamilton, Mark Sleeman
-
Patent number: 11773162Abstract: The invention provides methods and compositions for the treatment of cancer using anti-Siglec7 antibodies.Type: GrantFiled: August 4, 2017Date of Patent: October 3, 2023Assignee: Allakos, Inc.Inventors: Christopher Bebbington, Wouter Korver, Nenad Tomasevic, Suzy El Bader, Kenneth Luehrsen
-
Patent number: 11773165Abstract: Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.Type: GrantFiled: May 4, 2022Date of Patent: October 3, 2023Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ravindra Majeti, Irving L. Weissman
-
Patent number: 11760790Abstract: Antibodies and antigen binding fragments that specifically bind to HIV-1 Env and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: GrantFiled: February 21, 2019Date of Patent: September 19, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Paolo Lusso, Qingbo Liu, Peter Kwong, John Mascola, Young Do Kwon
-
Patent number: 11760791Abstract: Provided herein are monoclonal antibodies that specifically bind to melanin. The antibodies may be chimeric or humanized. Also provided herein are methods of use and methods of making the antibodies described. For example, the melanin antibodies may be used therapeutically to treat or prevent melanoma.Type: GrantFiled: September 13, 2018Date of Patent: September 19, 2023Assignee: RADIMMUNE THERAPEUTICS, INC.Inventors: Ekaterina Dadachova, David J. Rickles
-
Patent number: 11753655Abstract: The present disclosure provides methods and compositions for the treatment of diseases and/or disorders in a subject, including, but not limited to neurological disorders such as giant axonal neuropathy. The methods described herein include direct administration of a gene therapy (e.g. an rAAV viral vector) to a subject via injection into a vagus nerve (e.g. the left vagus nerve) of the subject.Type: GrantFiled: April 14, 2021Date of Patent: September 12, 2023Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Rachel M. Bailey, Steven J. Gray
-
Patent number: 11753469Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).Type: GrantFiled: August 10, 2020Date of Patent: September 12, 2023Assignee: Anji Bruno, LLCInventors: Luke Evnin, Jeanmarie Dean Guenot, Lori Kunkel
-
Patent number: 11753668Abstract: The present invention pertains to a cell culture medium comprising copper as a media supplement, which was shown to control recombinant protein glycosylation and methods of sing thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large scale cell culture.Type: GrantFiled: February 2, 2022Date of Patent: September 12, 2023Assignee: Biogen MA Inc.Inventors: Fernie Mitchelson, Erik Hughes, Jessica Mondia, Robin Parish Hyde-Deruyscher
-
Patent number: 11739149Abstract: The present inventors have successfully prepared an antigen-binding molecule comprising an antibody variable region that has binding activity against a molecule expressed on the surface of a T cell and a molecule expressed on the surface of any other immunocyte, but does not bind to these molecules at the same time. The present invention allows the preparation of an antigen-binding molecule capable of circumventing adverse reactions that may be caused by the cross-linking of T cells to other immunocytes, and provides an antigen-binding molecule suitable as a drug.Type: GrantFiled: December 5, 2019Date of Patent: August 29, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shojiro Kadono, Naoka Hironiwa, Mika Sakurai
-
Patent number: 11732048Abstract: The present disclosure relates to antibodies that specifically bind a novel epitope on the Axl protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.Type: GrantFiled: November 2, 2021Date of Patent: August 22, 2023Assignees: Bergen Teknologioverføring AS, BerGenBio ASAInventors: David Robert Micklem, Sergej Kiprijanov, James Bradley Lorens, Lavina Ahmed, Linn Nilsson, Tone Sandal
-
Patent number: 11732040Abstract: This invention relates to the dual targeting of cell inhibiting agents to the cell surface receptors CD7 and CD33 in the treatment of hematological malignancy. In particular, the invention relates to cell inhibiting agents that bispecifically binds to CD33 and CD7 for use in the treatment of a CD7+CD33+ hematological malignancy. Such agents may comprise bispecific antibody drug conjugates.Type: GrantFiled: November 27, 2018Date of Patent: August 22, 2023Assignee: BIVICTRIX LIMITEDInventor: Tiffany Jane Daniels
-
Patent number: 11732052Abstract: Provided is a bispecific (monoclonal) antibody molecule with a first binding domain binding an antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor specific antigen naturally occurring on the surface of a tumor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor. The (bispecific) antibody molecules can be used in a method for the treatment of particular diseases, wherein the (bispecific) antibody molecules are administered in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor in a specific treatment regimen.Type: GrantFiled: April 2, 2020Date of Patent: August 22, 2023Inventors: Carole Bourquin, Raffaella Castoldi, Stefan Endres, Christian Klein, Sebastian Kobold, Gerhard Niederfellner, Claudio Sustmann
-
Patent number: 11732045Abstract: The present invention relates to novel B7H6/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.Type: GrantFiled: October 1, 2020Date of Patent: August 22, 2023Assignee: Boehringer Ingelheim International GmbHInventors: Susanne Hipp, Paul Adam, Michael Dziegelewski, Rajkumar Ganesan, Philip Nicholas Gorman, Pankaj Gupta, Priyanka Gupta, Marcio Lasaro, Justin M. Scheer, Vladimir H. Voynov
-
Patent number: 11725024Abstract: The present disclosure provides antibody drug conjugates comprising STING modulators. Also provided are compositions comprising the antibody drug conjugates. The compounds and compositions are useful for stimulating an immune response in a subject in need thereof.Type: GrantFiled: April 27, 2022Date of Patent: August 15, 2023Assignee: Takeda Pharmaceutical Company LimitedInventors: He Xu, Hong Myung Lee, Christopher Arendt
-
Patent number: 11702470Abstract: Provided herein are methods for promoting axonal regeneration of sensory neurons and functional recovery of neurons following peripheral nerve injury in a subject experiencing aging-dependent nerve regenerative decline, the method comprising administering to a subject in need thereof an effective amount of an isolated binding molecule which specifically binds to CXCL13.Type: GrantFiled: June 8, 2021Date of Patent: July 18, 2023Assignee: IMPERIAL COLLEGE INNOVATIONS LIMITEDInventors: Simone Di Giovanni, Luming Zhou
-
Patent number: 11692040Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.Type: GrantFiled: May 17, 2021Date of Patent: July 4, 2023Assignee: ALS THERAPY DEVELOPMENT INSTITUTEInventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
-
Patent number: 11679082Abstract: Disclosed herein are therapeutic constructs including a delivery particle, at least one mitotic kinase inhibitor, and at least one immune checkpoint inhibitor. Also disclosed are therapeutic constructs including a mitotic kinase inhibitor, an immune checkpoint inhibitor, and a chemical linker. These therapeutic constructs cause cancer death by both therapeutic and immune effects and promote targeted delivery of more therapeutics to the surviving cancer cells in a positive feed-back loop. They enhance therapeutic index of free drugs and can be used intratumorally or systemically. This strategy can treat broad cancer types and is particular useful for cancer without obvious receptors for cancer-targeted delivery of otherwise toxic therapeutics.Type: GrantFiled: November 23, 2021Date of Patent: June 20, 2023Assignees: Oregon Health & Science University, PDX Pharmaceuticals, Inc.Inventors: Wassana Yantasee, Moataz Reda, Worapol Ngamcherdtrakul
-
Patent number: 11667723Abstract: Disclosed herein are fusion proteins having a first domain that activates an antigen-presenting cell (APC) (e.g., a dendritic cell) by binding to an activation receptor of the APC, and a second domain that activates an immune effector cell (e.g., a T cell) by targeting a co-stimulatory signaling pathway of the immune effector cell, as well as polynucleotides that encode such fusion proteins. Disclosed herein are also genetically engineered immune effector cells expressing such fusion protein, methods of their production, and their uses in treatment of diseases such as cancers.Type: GrantFiled: August 21, 2022Date of Patent: June 6, 2023Assignee: UTC Therapeutics (Shanghai) CO., LTD.Inventors: Yangbing Zhao, Xiaojun Liu, Xiaodong Song, Bin Li, Jintao Feng
-
Patent number: 11667717Abstract: Disclosed are antibodies binding to human IL-4R, having identical variable regions and different constant regions, wherein the variable regions can specifically bind to human IL-4R, and the constant regions affect the activity of the whole antibody through an amino acid site mutation. The above-mentioned antibodies can be used to treat diseases related to IL-4R overexpression, such as atopic dermatitis, asthma, etc., and thus possesses good clinical application prospects.Type: GrantFiled: August 20, 2019Date of Patent: June 6, 2023Assignee: SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD.Inventors: Jie Zhao, Liangfeng Jiang, Chen Chen, Huiling Wu, Yuping Huang, Haomin Huang, Zhenping Zhu
-
Patent number: 11660330Abstract: Disclosed are compositions and methods comprising the administration of pulsed dendritic cells and an immunoregulator molecule inhibitor for the treatment of cancer.Type: GrantFiled: June 19, 2020Date of Patent: May 30, 2023Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., VACCINEX, INC.Inventors: Brian Czerniecki, Krithika N. Kodumudi, Elizabeth Evans
-
Patent number: 11655457Abstract: In accordance with the present invention, CHO cells expressing a recombinant polypeptide of interest are grown in media where the amino acids, vitamins, phosphate, lipids and/or antioxidant optimization is utilized to manipulate and/or control the protein quality attributes of the polypeptides. Polypeptides expressed in accordance with the present invention may be advantageously used in the preparation of pharmaceutical compositions.Type: GrantFiled: June 2, 2022Date of Patent: May 23, 2023Assignee: Bristol-Myers Squibb CompanyInventor: Jun Tian
-
Patent number: 11643466Abstract: The present disclosure provides isolated binding molecules that bind to and blocks PD-L1, vectors comprising a nucleic acid molecules encoding an amino acid sequence of the binding molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring stimulation of immune responses including cancer.Type: GrantFiled: August 19, 2021Date of Patent: May 9, 2023Assignee: QLSF BIOTHERAPEUTICS INC.Inventor: Shihao Chen
-
Patent number: 11629200Abstract: The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.Type: GrantFiled: January 3, 2020Date of Patent: April 18, 2023Assignee: KLING BIOTHERAPEUTICS B.V.Inventors: Hergen Spits, Tim Beaumont, Marijn Aletta Gillissen, Adrianus Quirinus Bakker, Mette Deborah Hazenberg, Martijn Kedde
-
Patent number: 11629198Abstract: Compositions and methods are provided for loading cargoes onto red blood cells. Provided herein are novel antibodies, fragments, fusion proteins and other conjugates which specifically bind red blood cells via RHCE or Band 3.Type: GrantFiled: December 5, 2018Date of Patent: April 18, 2023Assignee: The Trustees of the University of PennsylvaniaInventors: Carlos H. Villa, Vladimir R. Muzykantov, Donald L. Siegel, Colin Greineder
-
Patent number: 11623954Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.Type: GrantFiled: July 9, 2018Date of Patent: April 11, 2023Assignee: INNATE PHARMAInventors: Stéphanie Cornen, Benjamin Rossi, Nicolai Wagtmann, Laurent Gauthier
-
Patent number: 11623949Abstract: The present application relates to neutralizing antibodies or antigen-binding fragments thereof against betacoronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to nucleic acid(s) encoding such neutralizing antibodies or antigen-binding fragments thereof, and to mixture and compositions comprising such antibodies, antigen-binding fragments or nucleic acids. Such neutralizing antibodies or antigen-binding fragments thereof are able to block betacoronavirus entry into cells and/or to induce complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP) against betacoronavirus-infected cells. Methods and uses of the antibodies, antigen-binding fragments thereof, nucleic acid(s) or compositions, including therapeutic, diagnostic, and preventative methods and uses for betacoronavirus infections and related diseases such as COVID-19, are also described.Type: GrantFiled: January 27, 2022Date of Patent: April 11, 2023Assignee: Talem Therapeutics LLCInventors: Ilse Roodink, Yasmina Noubia Abdiche, Jennifer L. Bath
-
Patent number: 11623965Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.Type: GrantFiled: August 14, 2018Date of Patent: April 11, 2023Assignee: Bristol-Myers Squibb CompanyInventors: Stanley R. Krystek, Jr., Yong Zhang, Gregory D. Vite, Arvind Rajpal, Chetana Rao-Naik, Paul E. Morin, Mohan Srinivasan, Zheng Lin, Virginie Lafont, Alla Pritsker
-
Patent number: 11608383Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.Type: GrantFiled: December 22, 2021Date of Patent: March 21, 2023Assignee: GENMAB A/SInventors: Brian Elliott, Tahamtan Ahmadi, Christopher W. L. Chiu, Esther C. W. Breij, Ida Hiemstra, Maria N. Jure-Kunkel
-
Patent number: 11608360Abstract: Peptides that form adhesive bonds, even in aqueous and/or saline environments, are disclosed. When aggregated, the peptides may be used in methods for producing hydrogels and/or adhesive materials. Synthetic peptide analogs are provided that are designed based on protein sequences found in barnacle adhesive, and may optionally be augmented with chemistry from other organisms that secrete proteins that adhere to substrates. The peptides may be used, for example, in biomedical and aqueous applications. Methods of using the aggregated peptides as adhesives are also provided.Type: GrantFiled: February 1, 2021Date of Patent: March 21, 2023Assignee: The Government of the United States of America, as represented by the Secretary of the NavyInventors: Christopher R. So, Kathryn J. Wahl
-
Patent number: 11603405Abstract: The present invention relates to antibodies that specifically bind CD3. The present invention relates to antibodies that specifically bind PSMA. The present invention relates to antibodies that specifically bind CD3 and PSMA. The present invention relates to antibodies that specifically bind IL1RAP. The present invention relates to antibodies that specifically bind CD33. The present invention relates to antibodies that specifically bind CD3 and IL1RAP. The present invention relates to antibodies that specifically bind CD3 and CD33. The present invention relates to antibodies that specifically bind TMEFF2. The present invention relates to antibodies that specifically bind CD3 and TMEFF2. The present invention relates to fragments of the antibodies, polynucleotides encoding the antibodies or fragments thereof, and methods of making and using the same.Type: GrantFiled: May 21, 2019Date of Patent: March 14, 2023Assignee: JANSSEN BIOTECH, INC.Inventors: Francois Gaudet, Jill Giles-Komar, Bradley Heidrich, Chichi Huang, Colleen Kane, Ronan McDaid, Jennifer Nemeth-Seay
-
Patent number: 11597765Abstract: Provided herein are methods for alleviating symptoms in a subject having Rett syndrome, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D).Type: GrantFiled: June 21, 2021Date of Patent: March 7, 2023Assignees: VACCINEX, INC., The Sydney Children's Hospital NetworkInventors: Yilin Mao, Wendy Gold, Elizabeth E. Evans, Maurice Zauderer
-
Patent number: 11591399Abstract: The present invention relates to anti-human PD-L2 antibodies, or the antigen binding parts thereof, which specifically bind human PD-L2 such that PD-L2 binding to PD-1 is blocked, wherein preferably said antibodies or antigen binding parts do not bind to mouse PD-L2 and human PD-L1 but bind to cyno PD-L2, preferably as determined by FACS analysis. The present invention also relates to nucleotide sequences encoding the anti-human PD-L2 antibodies, vectors and cells containing the nucleotide sequences. The antibodies and/or compositions of the invention are useful in human therapy, e.g., cancer therapy, and/or in cell-line based bioassays for determining T cell signalling.Type: GrantFiled: February 14, 2019Date of Patent: February 28, 2023Assignee: ABBA THERAPEUTICS AGInventors: Reto Simon Kohler, Gongda Xue, Lena Cron
-
Patent number: 11566063Abstract: Embodiments of the disclosure include methods and compositions for treatment of a medical condition related to the liver, including at least viral infections and liver cancer, for example. In specific embodiments, immunotherapies are provided for delivering polynucleotides locally to the liver, wherein the polynucleotides encode particular gene products that include bispecific antibodies, including those that target certain liver antigens, for example.Type: GrantFiled: September 29, 2017Date of Patent: January 31, 2023Assignee: BAYLOR COLLEGE OF MEDICINEInventors: Robert Layne Kruse, Karl-Dimiter Bissig, Stephen M. G. Gottschalk, Thomas C. T. Shum
-
Patent number: 11560437Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having a particular set of mutations at the interface of the CH1 and CL domains, the mutations preventing heavy chain/light chain mispairing.Type: GrantFiled: March 27, 2018Date of Patent: January 24, 2023Assignee: BIOMUNEX PHARMACEUTICALSInventors: Eugene Zhukovsky, Olivier Leger, Richard J. Morse
-
Patent number: 11560416Abstract: A method for producing a dual function protein includes a biologically active protein and an FGF21 mutant protein. The method allows stable production of a target protein by effectively preventing decomposition of the target protein, and thus has a high potential for commercial usage.Type: GrantFiled: April 20, 2018Date of Patent: January 24, 2023Assignee: YUHAN CORPORATIONInventors: Byung Hyun Choi, In Hwan Lim, Jun Young Park, Jin Hyoung Lee, Ki Hong Kim, Hae Yong Jo, Jun Hwan Kim, Moo Young Song, Jong Gyun Kim
-
Patent number: 11555078Abstract: Provided herein are multispecific antibodies that selectively bind to PSMA and effector cell antigens such as CD3, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.Type: GrantFiled: December 7, 2021Date of Patent: January 17, 2023Assignee: JANUX THERAPEUTICS, INC.Inventors: David Campbell, Thomas R. DiRaimondo
-
Patent number: 11549108Abstract: The invention relates to the field of cell culture technology. It concerns the knockdown, using RNA interference, or gene knockout, of activating transcription factor 6 beta (ATF6B), or the combination of ceramide synthase 2 (CERS2) and TBC1 domain family member 20 (TBC1D20) proteins, which play central roles in the cellular secretion pathway. This downregulation leads to improved secretion of biopharmaceutically relevant products produced in mammalian cells. The invention specifically relates to mammalian cells having enhanced secretion of a recombinant therapeutic protein compared to a control cell, a method of producing said mammalian cell, a method for the production of a recombinant secreted therapeutic protein and the use of said mammalian cell for increasing the yield of a recombinant secreted therapeutic protein.Type: GrantFiled: November 2, 2020Date of Patent: January 10, 2023Assignee: Boehringer Ingelheim International GmbHInventors: Monilola Olayioye, Angelika Hausser, Lisa Pieper, Michaela Strotbek, Till Wenger
-
Patent number: 11542329Abstract: The present disclosure provides antibodies or antibody fragments specific for GPVI. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment or prophylaxis of GPVI related disorders or conditions, such as for example thrombotic or vascular disorders.Type: GrantFiled: May 15, 2019Date of Patent: January 3, 2023Assignee: Morphosys AGInventors: Kerstin Uhland, Julia Neugebauer, Steffen Runz
-
Patent number: 11535668Abstract: Disclosed herein are inducible monovalent target-binding proteins which are activated upon protease cleavage. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.Type: GrantFiled: February 28, 2018Date of Patent: December 27, 2022Assignee: HARPOON THERAPEUTICS, INC.Inventors: Patrick Baeuerle, Holger Wesche